Shares of Gilead Sciences, Inc. GILD were down 2.47% after the Wall Street Journal reported that The Health and Human ...

The Fed kept rates unchanged for now, a move that was widely expected. It did note, though, that “uncertainty around the ...

The average brokerage recommendation (ABR) for Gilead (GILD) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after ...

The recombinant zoster vaccine is effective in preventing herpes zoster in adults aged 50 years or older with rheumatoid ...

In a report released today, Asthika Goonewardene from Truist Financial maintained a Hold rating on Gilead Sciences (GILD – Research Report).

Shares of Gilead Sciences, Inc. dropped nearly 2.5% on Wednesday and extended losses after hours following a report that the ...

The S&P 500 added 1.1% on Wednesday, March 19, 2025, as the Fed held interest rates steady, reaffirming plans for future cuts ...

With cancer diagnoses and death rates in Michigan often higher than the national average, a new, patient-centered ...

The Department of Health and Human Services (HHS) is reportedly poised to slash funding for domestic HIV prevention at the ...

Investing.com -- Gilead Sciences shares dropped more than 3% Wednesday following a Wall Street Journal report that the Health ...

Gilead Sciences has been one of the best-performing large biotech companies over the past year, rising about 50%. That is largely due to excitement over its [long-acting HIV prevention drug]( ...

Gilead Sciences, Inc. (GILD) is currently at $106.30, down $3.94 or 3.57% --Would be lowest close since Feb. 18, 2025, when it closed at $105.25 --On pace for largest percent decrease since Nov. 15, ...